Warning Letter: Matheson Tri-Gas

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Dallas, TX (Nov. 7)-The US Food and Drug Administration has posted a Warning Letter from its Dallas District office to Matheson Tri-Gas, Inc.

Dallas, TX (Nov. 7)-The US Food and Drug Administration has posted a Warning Letter (http://www.fda.gov/foi/warning_letters/g6096d.htm) from its Dallas District office to Matheson Tri-Gas, Inc. (Parsippany, NJ, www.mathesontrigas.com). The three-page letter, dated Sept. 12, detailed findings of inspections, in March and April of this year, of a Matheson medical gas facility in Houston, and reviewed the company's April 19 response to the inspectors' Form 483 observations.

The Warning includes three citations, noting shortcomings in:

  • establishing specifications, standards, sampling plans, and test procedures to assure identity, strength, quality, and purity [211 CFR 211.160(b)]-specifically in what the Agency described as inadequate testing of incoming USP carbon dioxide and helium gas supplies.

  • establishing and documenting "the accuracy, sensitivity, specificity, and reproducibility" of test methods [21 CFR § 211.165(e)]-specifically failing to validate a gas-chromatographic carbon-dioxide assay.

  • establishing "an adequate quality control unit that shall have the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products, and the authority to review production records to assure that no errors have occurred, or, if errors have occurred, that they have been fully investigated" [211 CFR § 211.22]. The Warning cited the quality control unit's failure, in the two previous citations, to ensure testing of incoming drug product with a validated test method.
Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes